Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Infectious diseases · JAMA · 2026-10-20
RCTn = 600
Woods et al. Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical TrialInfectious diseases · J Antimicrob Chemother · 2026-10-06
RCTn = 114
Palich et al. Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)Infectious diseases · J Infect Dis · 2026-09-23
Secondary analysisn = 1,227
Diamond et al. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNAInfectious diseases · Clin Infect Dis · 2026-07-23
RCTn = 147
Koethe et al. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)Infectious diseases · Lancet HIV · 2026-02-25
RCTn = 536
Rockstroh et al. Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialInfectious diseases · Lancet · 2026-02-07
RCTn = 514
Colson et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialInfectious diseases · Lancet · 2026-02-07
RCTn = 553
Orkin et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial